108 results on '"Bengtson, Lindsay G. S."'
Search Results
2. Burden of illness in progressive fibrosing interstitial lung disease
- Author
-
Singer, David, primary, Bengtson, Lindsay G S, additional, Conoscenti, Craig S, additional, Anderson, Amy J, additional, Brekke, Lee, additional, Shetty, Sharash S, additional, and Brown, Kevin K, additional
- Published
- 2022
- Full Text
- View/download PDF
3. Claims-based Prevalence of Disease Progression among Patients with Fibrosing Interstitial Lung Disease Other than Idiopathic Pulmonary Fibrosis in the United States
- Author
-
Singer, David, primary, Bengtson, Lindsay G. S., additional, Conoscenti, Craig S., additional, Laouri, Marianne, additional, Shetty, Sharash S., additional, Anderson, Amy J., additional, and Brown, Kevin K., additional
- Published
- 2022
- Full Text
- View/download PDF
4. Oral anticoagulants and liver injury: the threat of uncontrolled confounding
- Author
-
Alonso, Alvaro, MacLehose, Richard F, Chen, Lin Yee, Bengtson, Lindsay G S, Chamberlain, Alanna M, Norby, Faye L, and Lutsey, Pamela L
- Published
- 2018
- Full Text
- View/download PDF
5. Meningococcal Vaccination Rates Among People With a New Diagnosis of HIV Infection in the US
- Author
-
Ghaswalla, Parinaz K., primary, Marshall, Gary S., additional, Bengtson, Lindsay G. S., additional, Buikema, Ami R., additional, Bancroft, Tim, additional, Koep, Eleena, additional, Novy, Patricia, additional, and Hogea, Cosmina S., additional
- Published
- 2022
- Full Text
- View/download PDF
6. Impact of timing of nintedanib initiation among patients newly diagnosed with idiopathic pulmonary fibrosis
- Author
-
Singer, David, primary, Bengtson, Lindsay G. S., additional, Conoscenti, Craig S., additional, Anderson, Amy J., additional, Brekke, Lee, additional, Shetty, Sharash S., additional, and de Andrade, Joao, additional
- Published
- 2022
- Full Text
- View/download PDF
7. Low Meningococcal Vaccination Rates Among Patients With Newly Diagnosed Complement Component Deficiencies in the United States
- Author
-
Marshall, Gary S, primary, Ghaswalla, Parinaz K, additional, Bengtson, Lindsay G S, additional, Buikema, Ami R, additional, Bancroft, Tim, additional, Koep, Eleena, additional, Novy, Patricia, additional, and Hogea, Cosmina S, additional
- Published
- 2021
- Full Text
- View/download PDF
8. Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies
- Author
-
Palli, Swetha R, primary, Xie, Bin, additional, Chastek, Benjamin, additional, Elliott, Caitlin A, additional, and Bengtson, Lindsay G S, additional
- Published
- 2021
- Full Text
- View/download PDF
9. Clinical and economic burden of chronic rhinosinusitis with nasal polyposis: A U.S. administrative claims analysis.
- Author
-
Peters, Anju T., Bengtson, Lindsay G. S., Yen Chung, Emmanuel, Benjamin, Katial, Rohit K., Kreindler, James L., Blauer-Peterson, Cori J., and Davis, Greg E.
- Subjects
ASTHMATICS ,NASAL polyps ,SINUSITIS ,MEDICAL care costs ,SECONDARY analysis ,STANDARD deviations ,ASTHMA - Abstract
Background: Limited data exist on the clinical and economic burden of chronic rhinosinusitis with nasal polyposis (CRSwNP). Objective: To describe patient characteristics, health-care resource utilization (HCRU), and health-care costs among patients with CRSwNP with and without comorbid asthma (primary analysis) and with surgical management of nasal polyps (secondary analysis). Methods: This was a retrospective study of patients diagnosed with CRSwNP conducted using administrative claims data from January 1, 2013, through March 31, 2019. Study outcomes were assessed over a 2-year follow-up. Results were stratified by baseline asthma status (primary analysis) and presented separately for patients with surgically managed CRSwNP (secondary analysis). Results: The primary analysis included 10,999 patients with CRSwNP (2649 with asthma, 8350 without asthma). Patients with versus without asthma had higher medication use, HCRU, and all-cause medical costs (mean 6 standard deviation $34,667 6 $42,234 versus $27,122 6 $45,573; p < 0.001) across the full follow-up period. CRSwNP-related medical costs were significantly higher for patients with versus without asthma in year 2 of follow-up. In the surgical management analysis (n = 4943), most categories of medication use and CRSwNP-related HCRU declined from baseline levels during follow-up, and CRSwNP-related pharmacy costs in year 2 were less than half of baseline levels. Conclusion: Patients diagnosed with CRSwNP and asthma had a greater burden of illness than those without asthma. Higher CRSwNP-related medical costs in year 2 of follow-up for patients with asthma may indicate worsening symptoms over time. Among patients with surgically managed CRSwNP, HCRU and costs increased in year 1 of follow-up but decreased below baseline levels in year 2, potentially reflecting improved symptom severity. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
10. Low Meningococcal Vaccination Rates Among Patients With Newly Diagnosed Complement Component Deficiencies in the United States.
- Author
-
Marshall, Gary S, Ghaswalla, Parinaz K, Bengtson, Lindsay G S, Buikema, Ami R, Bancroft, Tim, Koep, Eleena, Novy, Patricia, and Hogea, Cosmina S
- Subjects
AUTOIMMUNE disease diagnosis ,IMMUNIZATION ,COMPLEMENT (Immunology) ,TIME ,AUTOIMMUNE diseases ,RETROSPECTIVE studies ,MENINGOCOCCAL vaccines ,DESCRIPTIVE statistics ,NEISSERIA meningitidis - Abstract
Meningococcal vaccination is recommended for patients with complement component deficiencies (CDs) in the United States. In this retrospective database study, only 4.6% and 2.2% of patients received MenACWY and MenB vaccination, respectively, within 3 years of CD diagnosis. Thus, meningococcal vaccination rates among patients with CDs need to be improved. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Development and validation of a drug adherence index for COPD
- Author
-
Bengtson, Lindsay G S, primary, Bancroft, Tim, additional, Schilling, Craig, additional, Buikema, Ami R, additional, and Stanford, Richard H, additional
- Published
- 2021
- Full Text
- View/download PDF
12. Economic impact of cardiac implantable electronic device infections: cost analysis at one year in a large U.S. health insurer
- Author
-
Eby, Elizabeth L., Bengtson, Lindsay G. S., Johnson, Michael P., Burton, Mark L., and Hinnenthal, Jennifer
- Abstract
Aims: Cardiac device infections (CDIs) are serious adverse events associated with morbidity and mortality, significant costs and increased healthcare utilization. The objective of the current study was to characterize the CDI rate by device type, risk factors for infection and healthcare costs from a large U.S. health insurer perspective. Materials and Methods: A retrospective analysis of a large U.S. health insurer database identified commercial and Medicare Advantage with Part D (MAPD) members ≥18 years with ≥1 claim for a cardiac implantable electronic device (CIED) procedure between 01 October 2011 and 31 October 2015. CIEDs included pacemakers (IPG), implantable cardioverter defibrillators (ICDs), and cardiac resynchronization therapy – pacemakers without (CRT-P) and with defibrillation (CRT-D). Probabilities of CDI through one-year post implant were estimated using the Kaplan–Meier method. A regression model with stepwise variable selection was used to select risk factors associated with CDIs. Results: A total of 63,406 patients were included with an overall CDI rate of 1.28% (1.0% de novo and 1.74% replacement devices), varying by device type: IPG = 0.91%; ICD = 1.63%; CRT-p = 1.50%; CRT-D = 2.22%. The average adjusted annual medical costs were 2.4 times greater [95% confidence interval (CI) = 2.1–2.7] for those with an infection compared to those without, and the incremental cost difference was estimated to be $57,322 [95% CI $46,572–$70,484]. Observed risk factors of CDIs included prior device infection [Odds ratio (OR) = 11.356; 95% CI = 7.923–16.276], undergoing a CIED replacement procedure (OR = 1.644; 95% CI = 1.361–1.987), implantation of a high-power device (OR = 1.354; 95% CI = 1.115–1.643), and younger age (age < 65) (OR = 1.607; 95% CI = 1.307–1.976). Conclusions: The CDI rate at one year ranged from 0.91%–2.22% depending on device type. Management of CDIs among commercial and MAPD members is associated with high healthcare expenditures.
- Published
- 2020
- Full Text
- View/download PDF
13. Economic impact of cardiac implantable electronic device infections: cost analysis at one year in a large U.S. health insurer
- Author
-
Eby, Elizabeth L., primary, Bengtson, Lindsay G. S., additional, Johnson, Michael P., additional, Burton, Mark L., additional, and Hinnenthal, Jennifer, additional
- Published
- 2020
- Full Text
- View/download PDF
14. Sex and racial differences in cardiovascular disease risk in patients with atrial fibrillation
- Author
-
O’Neal, Wesley T., primary, Alam, Aniqa B., additional, Sandesara, Pratik B., additional, Claxton, J’Neka S., additional, MacLehose, Richard F., additional, Chen, Lin Y., additional, Bengtson, Lindsay G. S., additional, Chamberlain, Alanna M., additional, Norby, Faye L., additional, Lutsey, Pamela L., additional, and Alonso, Alvaro, additional
- Published
- 2019
- Full Text
- View/download PDF
15. Association of Oral Anticoagulant Type With Risk of Dementia Among Patients With Nonvalvular Atrial Fibrillation
- Author
-
Chen, Nemin, primary, Lutsey, Pamela L., additional, MacLehose, Richard F., additional, Claxton, J'Neka S., additional, Norby, Faye L., additional, Chamberlain, Alanna M., additional, Bengtson, Lindsay G. S., additional, O'Neal, Wesley T., additional, Chen, Lin Y., additional, and Alonso, Alvaro, additional
- Published
- 2018
- Full Text
- View/download PDF
16. A new model to predict major bleeding in patients with atrial fibrillation using warfarin or direct oral anticoagulants
- Author
-
Claxton, J’Neka S., primary, MacLehose, Richard F., additional, Lutsey, Pamela L., additional, Norby, Faye L., additional, Chen, Lin Y., additional, O’Neal, Wesley T., additional, Chamberlain, Alanna M., additional, Bengtson, Lindsay G. S., additional, and Alonso, Alvaro, additional
- Published
- 2018
- Full Text
- View/download PDF
17. Frequency of Care and Mortality Following an Incident Diagnosis of Peripheral Artery Disease in the Inpatient or Outpatient Setting: The ARIC (Atherosclerosis Risk in Communities) Study
- Author
-
Kalbaugh, Corey A., primary, Loehr, Laura, additional, Wruck, Lisa, additional, Lund, Jennifer L., additional, Matsushita, Kunihiro, additional, Bengtson, Lindsay G. S., additional, Heiss, Gerardo, additional, and Kucharska‐Newton, Anna, additional
- Published
- 2018
- Full Text
- View/download PDF
18. Provider Specialty, Anticoagulation Prescription Patterns, and Stroke Risk in Atrial Fibrillation
- Author
-
O'Neal, Wesley T., primary, Sandesara, Pratik B., additional, Claxton, J'Neka S., additional, MacLehose, Richard F., additional, Chen, Lin Y., additional, Bengtson, Lindsay G. S., additional, Chamberlain, Alanna M., additional, Norby, Faye L., additional, Lutsey, Pamela L., additional, and Alonso, Alvaro, additional
- Published
- 2018
- Full Text
- View/download PDF
19. Oral anticoagulants and liver injury: the threat of uncontrolled confounding
- Author
-
Alonso, Alvaro, primary, MacLehose, Richard F, additional, Chen, Lin Yee, additional, Bengtson, Lindsay G S, additional, Chamberlain, Alanna M, additional, Norby, Faye L, additional, and Lutsey, Pamela L, additional
- Published
- 2017
- Full Text
- View/download PDF
20. Inhaled Corticosteroid-Containing Treatment Escalation and Outcomes for Patients with Asthma in a U.S. Health Care Organization
- Author
-
Bengtson, Lindsay G. S., primary, Yu, Yanni, additional, Wang, Weijia, additional, Cao, Feng, additional, Hulbert, Erin M., additional, Wolbeck, Ryan, additional, Elliott, Caitlin A., additional, and Buikema, Ami R., additional
- Published
- 2017
- Full Text
- View/download PDF
21. Economic Outcomes of First-Line Regimen Switching Among Stable Patients with HIV
- Author
-
Rosenblatt, Lisa, primary, Buikema, Ami R., additional, Seare, Jerry, additional, Bengtson, Lindsay G. S., additional, Johnson, Jonathan, additional, Cao, Feng, additional, and Villasis-Keever, Angelina, additional
- Published
- 2017
- Full Text
- View/download PDF
22. Peripheral Artery Disease Prevalence and Incidence Estimated From Both Outpatient and Inpatient Settings Among Medicare Fee‐for‐Service Beneficiaries in the Atherosclerosis Risk in Communities (ARIC) Study
- Author
-
Kalbaugh, Corey A., primary, Kucharska‐Newton, Anna, additional, Wruck, Lisa, additional, Lund, Jennifer L., additional, Selvin, Elizabeth, additional, Matsushita, Kunihiro, additional, Bengtson, Lindsay G. S., additional, Heiss, Gerardo, additional, and Loehr, Laura, additional
- Published
- 2017
- Full Text
- View/download PDF
23. Association of Oral Anticoagulant Type With Risk of Dementia Among Patients With Nonvalvular Atrial Fibrillation.
- Author
-
Nemin Chen, Lutsey, Pamela L., MacLehose, Richard F., Claxton, J'Neka S., Norby, Faye L., Chamberlain, Alanna M., Bengtson, Lindsay G. S., O'Neal, Wesley T., Chen, Lin Y., Alonso, Alvaro, and Chen, Nemin
- Published
- 2018
- Full Text
- View/download PDF
24. Impact of Atrial Fibrillation on Healthcare Utilization in the Community: The Atherosclerosis Risk in Communities Study
- Author
-
Bengtson, Lindsay G. S., primary, Lutsey, Pamela L., additional, Loehr, Laura R., additional, Kucharska‐Newton, Anna, additional, Chen, Lin Y., additional, Chamberlain, Alanna M., additional, Wruck, Lisa M., additional, Duval, Sue, additional, Stearns, Sally C., additional, and Alonso, Alvaro, additional
- Published
- 2014
- Full Text
- View/download PDF
25. Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation.
- Author
-
Norby, Faye, Bengtson, Lindsay, Lutsey, Pamela, Chen, Lin, MacLehose, Richard, Chamberlain, Alanna, Rapson, Ian, Alonso, Alvaro, Norby, Faye L, Bengtson, Lindsay G S, Lutsey, Pamela L, Chen, Lin Y, MacLehose, Richard F, and Chamberlain, Alanna M
- Subjects
ATRIAL fibrillation ,ATRIAL fibrillation treatment ,RIVAROXABAN ,DRUG therapy ,WARFARIN ,MYOCARDIAL infarction ,PATIENTS ,THERAPEUTICS ,ATRIAL fibrillation diagnosis ,STROKE prevention ,STROKE diagnosis ,ANTICOAGULANTS ,BLOOD coagulation ,COMPARATIVE studies ,DATABASES ,HEMORRHAGE ,RESEARCH methodology ,MEDICAL care research ,MEDICAL cooperation ,MULTIVARIATE analysis ,ORAL drug administration ,PROTEINS ,RESEARCH ,STROKE ,TIME ,EVALUATION research ,TREATMENT effectiveness ,PROPORTIONAL hazards models ,RETROSPECTIVE studies ,CASE-control method ,ODDS ratio ,DISEASE complications - Abstract
Background: Rivaroxaban is an oral anticoagulant approved in the US for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). We determined the effectiveness and associated risks of rivaroxaban versus other oral anticoagulants in a large real-world population.Methods: We selected NVAF patients initiating oral anticoagulant use in 2010-2014 enrolled in MarketScan databases. Rivaroxaban users were matched with warfarin and dabigatran users by age, sex, enrolment date, anticoagulant initiation date, and high-dimensional propensity score. Study endpoints, including ischemic stroke, intracranial bleeding (ICB), myocardial infarction (MI), and gastrointestinal (GI) bleeding, were identified from inpatient diagnostic codes. Multivariable Cox models were used to assess associations between type of anticoagulant and outcomes.Results: The analysis included 44,340 rivaroxaban users matched to 89,400 warfarin and 16,957 dabigatran users (38% female, mean age 70) with 12 months of mean follow-up. Anticoagulant-naïve rivaroxaban initiators, but not those switching from warfarin, had lower risk of ischemic stroke [hazard ratio (HR) (95% confidence interval (CI)): 0.75 (0.62, 0.91)] and ICB [HR (95%CI): 0.55, (0.39, 0.78)] than warfarin users. In contrast, anticoagulant-experienced rivaroxaban initiators had higher risk of GI bleeding than warfarin users [HR (95%CI): 1.55 (1.32, 1.83)]. Endpoint rates were similar when comparing anticoagulant-naïve rivaroxaban and dabigatran initiators, with the exception of higher GI bleeding risk in rivaroxaban users [HR (95%CI) 1.28 (1.06, 1.54)]. There were no significant differences in the risk of MI among the comparison groups.Conclusion: In this large real-world sample of NVAF patients, effectiveness and risks of rivaroxaban versus warfarin differed by prior anticoagulant status, while effectiveness of rivaroxaban versus dabigatran differed in GI bleeding risk. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
26. Prospective study of oral anticoagulants and risk of liver injury in patients with atrial ?brillation.
- Author
-
Alonso, Alvaro, MacLehose, Richard F., Chen, Lin Y., Bengtson, Lindsay G. S., Chamberlain, Alanna M., Norby, Faye L., and Lutsey, Pamela L.
- Subjects
ANTICOAGULANTS ,LIVER injuries ,ATRIAL fibrillation ,HOSPITAL care ,DRUG therapy ,WARFARIN ,DABIGATRAN ,RIVAROXABAN ,INJURY risk factors - Published
- 2017
- Full Text
- View/download PDF
27. Lifetime Risk and Risk Factors for Abdominal Aortic Aneurysm in a 24-Year Prospective Study.
- Author
-
Weihong Tang, Lu Yao, Roetker, Nicholas S., Alonso, Alvaro, Lutsey, Pamela L., Steenson, Carol C., Lederle, Frank A., Hunter, David W., Bengtson, Lindsay G. S., Guan, Weihua, Missov, Emil, and Folsom, Aaron R.
- Published
- 2016
- Full Text
- View/download PDF
28. Comparable Ascertainment of Newly-Diagnosed Atrial Fibrillation Using Active Cohort Follow-Up versus Surveillance of Centers for Medicare and Medicaid Services in the Atherosclerosis Risk in Communities Study
- Author
-
Bengtson, Lindsay G. S., primary, Kucharska-Newton, Anna, additional, Wruck, Lisa M., additional, Loehr, Laura R., additional, Folsom, Aaron R., additional, Chen, Lin Y., additional, Rosamond, Wayne D., additional, Duval, Sue, additional, Lutsey, Pamela L., additional, Stearns, Sally C., additional, Sueta, Carla, additional, Yeh, Hsin-Chieh, additional, Fox, Ervin, additional, and Alonso, Alvaro, additional
- Published
- 2014
- Full Text
- View/download PDF
29. A Rising Tide
- Author
-
Alonso, Alvaro, primary and Bengtson, Lindsay G. S., additional
- Published
- 2014
- Full Text
- View/download PDF
30. Trajectories of Cardiovascular Risk Factors and Incidence of Atrial Fibrillation Over a 25-Year Follow-Up: The ARIC Study (Atherosclerosis Risk in Communities).
- Author
-
Norby, Faye L., Soliman, Elsayed Z., Chen, Lin Y., Bengtson, Lindsay G. S., Loehr, Laura R., Agarwal, Sunil K., and Alonso, Alvaro
- Published
- 2016
- Full Text
- View/download PDF
31. Obstructive Sleep Apnea and 15-Year Cognitive Decline: The Atherosclerosis Risk in Communities (ARIC) Study.
- Author
-
Lutsey, Pamela L, Bengtson, Lindsay G S, Punjabi, Naresh M, Shahar, Eyal, Mosley, Thomas H, Gottesman, Rebecca F, Wruck, Lisa M, MacLehose, Richard F, and Alonso, Alvaro
- Abstract
Prospective data evaluating abnormal sleep quality and quantity with cognitive decline are limited because most studies used subjective data and/or had short follow-up. We hypothesized that, over 15 y of follow-up, participants with objectively measured obstructive sleep apnea (OSA) and other indices of poor sleep quantity and quality would experience greater decline in cognitive functioning than participants with normal sleep patterns.
- Published
- 2016
- Full Text
- View/download PDF
32. Temporal Trends in the Occurrence and Outcomes of Atrial Fibrillation in Patients With Acute Myocardial Infarction (from the Atherosclerosis Risk in Communities Surveillance Study).
- Author
-
Bengtson, Lindsay G. S., Chen, Lin Y., Chamberlain, Alanna M., Michos, Erin D., Whitsel, Eric A., Lutsey, Pamela L., Duval, Sue, Rosamond, Wayne D., and Alonso, Alvaro
- Subjects
- *
ATRIAL fibrillation , *MYOCARDIAL infarction , *HEALTH outcome assessment , *CORONARY disease , *ATHEROSCLEROSIS , *STROKE-related mortality , *DEATH rate , *ASPIRIN , *PATIENTS - Abstract
Atrial fibrillation (AF) frequently coexists in the setting of myocardial infarction (MI), being associated with increased mortality. Nonetheless, temporal trends in the occurrence of AF complicating MI and in the prognosis of these patients are not well described. We examined temporal trends in prevalence of AF in the setting of MI and the effect of AF on prognosis in the community. We studied a population-based sample of 20,049 validated first-incident nonfatal hospitalized MIs among 35- to 74-year old residents of 4 communities in the Atherosclerosis Risk in Communities (ARIC) Study from 1987 through 2009. Prevalence of AF in the setting of MI increased from 11% to 15% during the 23-year study period. The multivariable adjusted odds ratio for prevalent AF, per 5-year increment, was 1.11 (95% confidence interval 1.04 to 1.19). Overall, in patients with MI, AF was associated with increased 1-year case fatality (odds ratio 1.47, 95% confidence interval 1.07 to 2.01) compared with those without AF. However, there was no evidence that the impact of AF on MI survival changed over time or differed over time by sex, race, or MI classification (all p values >0.10). In conclusion, co-occurrence of AF in MI slightly increased between 1987 and 2009. The adverse impact of AF on survival in the setting of MI was consistent throughout. In the setting of MI, co-occurrence of AF should be viewed as a critical clinical event, and treatment needs unique to this population should be explored further. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
33. Intracranial Hemorrhage Mortality in Atrial Fibrillation Patients Treated With Dabigatran or Warfarin.
- Author
-
Alonso, Alvaro, Bengtson, Lindsay G. S., MacLehose, Richard F., Lutsey, Pamela L., Chen, Lin Y., and Lakshminarayan, Kamakshi
- Published
- 2014
- Full Text
- View/download PDF
34. Comparable Ascertainment of Newly-Diagnosed Atrial Fibrillation Using Active Cohort Follow-Up versus Surveillance of Centers for Medicare and Medicaid Services in the Atherosclerosis Risk in Communities Study
- Author
-
Folsom, Aaron R., Wruck, Lisa M., Stearns, Sally C., Duval, Sue, Loehr, Laura R., Sueta, Carla, Kucharska-Newton, Anna, Alonso, Alvaro, Fox, Ervin, Chen, Lin Y., Lutsey, Pamela L., Bengtson, Lindsay G. S., Yeh, Hsin-Chieh, and Rosamond, Wayne D.
- Subjects
3. Good health - Abstract
Increasingly, epidemiologic studies use administrative data to identify atrial fibrillation (AF). Capture of incident AF is not well documented. We examined incidence rates and concordance of AF diagnosis based on active cohort follow-up versus surveillance of Centers for Medicare and Medicaid Services data in the Atherosclerosis Risk in Communities study.
35. A rising tide: the global epidemic of atrial fibrillation.
- Author
-
Alonso, Alvaro and Bengtson, Lindsay G S
- Published
- 2014
- Full Text
- View/download PDF
36. Outcomes Following Initiation of Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol versus Multiple-Inhaler Triple Therapy Among Medicare Advantage with Part D Beneficiaries and Those Commercially Enrolled for Health Care Insurance in the United States.
- Author
-
Bogart M, Bengtson LGS, Johnson MG, Bunner SH, Gronroos NN, and DiRocco KK
- Subjects
- Humans, Aged, United States, Bronchodilator Agents, Retrospective Studies, Administration, Inhalation, Fluticasone therapeutic use, Nebulizers and Vaporizers, Benzyl Alcohols, Chlorobenzenes, Quinuclidines, Delivery of Health Care, Drug Combinations, Pulmonary Disease, Chronic Obstructive diagnosis, Pulmonary Disease, Chronic Obstructive drug therapy, Medicare Part C, Androstadienes
- Abstract
Purpose: Patients with chronic obstructive pulmonary disease (COPD) have been shown to benefit from triple therapy commonly delivered by multiple-inhaler triple therapy (MITT); however, the complexity of MITT regimens may decrease patient adherence. Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI), a once-daily single-inhaler triple therapy (SITT), became available in the United States (US) in 2017, but real-world data comparing outcomes for SITT versus MITT are currently limited. This study compared outcomes among patients with COPD initiating MITT versus SITT with FF/UMEC/VI who were either Medicare Advantage with Part D (MAPD) beneficiaries or commercial enrollees in the US., Methods: Retrospective study using administrative claims data from the Optum Research Database for patients with COPD who initiated FF/UMEC/VI or MITT between September 1, 2017, and March 31, 2019 (index date: first pharmacy claim for FF/UMEC/VI cohort; earliest day of ≥30 consecutive days-long period of overlap in the day's supply of all triple therapy components for MITT cohort). COPD exacerbations, adherence to triple therapy, and all-cause and COPD-related health care resource utilization (HCRU) and costs were compared between FF/UMEC/VI and MITT initiators., Results: In total, 4659 FF/UMEC/VI initiators and 9845 MITT initiators for the MAPD population, and 821 FF/UMEC/VI initiators and 1893 MITT initiators for the commercial population were included in the study. MAPD beneficiaries initiating FF/UMEC/VI had a significantly lower annual rate of severe exacerbations compared to MITT initiators (0.26 vs 0.29; p=0.014). They also had a significantly higher mean adherence (proportion of days covered) (0.51 vs 0.37; p<0.001) and significantly lower all-cause and COPD-related inpatient stays compared to MITT initiators ([32.02% vs 34.27%; p=0.017], [16.09% vs 17.72%; p=0.037]). Trends were similar among the commercial population, but the results were not statistically significant., Conclusion: FF/UMEC/VI initiators had significantly fewer severe exacerbations, higher triple therapy adherence, and lower HCRU costs compared to MITT initiators for MAPD beneficiaries., Competing Interests: MB was an employee of GSK and held stock/shares in GSK at the time of the study conduct. KKD is an employee of GSK and holds stock/shares in GSK. LGSB, MGJ, NNG, and SHB are/were employees of Optum, which received research funds from GSK to conduct this study. Current affiliation details for MB: Gilead Sciences, Foster City, CA, USA. Current affiliation details for LGSB: Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA (Boehringer Ingelheim has no connection to this study). Current affiliation details for SHB: Genesis Research, Hoboken, NJ, USA., (© 2024 Bogart et al.)
- Published
- 2024
- Full Text
- View/download PDF
37. Real-world primary nonadherence to antiobesity medications.
- Author
-
Kan H, Bae JP, Dunn JP, Buysman EK, Gronroos NN, Swindle JP, Bengtson LGS, and Ahmad N
- Subjects
- Humans, Female, Retrospective Studies, Obesity drug therapy, Obesity epidemiology, Delivery of Health Care, Overweight, Anti-Obesity Agents therapeutic use
- Abstract
BACKGROUND: Primary nonadherence (PNA), when a medication is newly prescribed but not filled, has been identified as a major research gap potentially impacting the optimal treatment of patients with overweight and obesity who are newly prescribed antiobesity medications (AOMs). OBJECTIVES: To assess PNA among patients with newly prescribed AOMs and to examine factors associated with PNA to AOMs. METHODS: This was a retrospective study that used the Optum Integrated Clinical plus Claims database to identify individuals who had at least 1 prescription order for an AOM the US Food and Drug Administration approved for long-term use. Individuals with prescription orders between January 1, 2012, and February 28, 2019, were identified, and patient demographics, clinical characteristics, medication prescribed, baseline health care utilization, and obesity-related complications were described by PNA status. PNA was defined as no pharmacy claim for the AOM within 60 days of the date of the new prescription order as identified in electronic health record data. A multivariable logistic regression model was used to examine factors associated with PNA. RESULTS: The study sample included a total of 1,563 patients. The mean body mass index was 38.4 kg/m
2 ; 10.7% were prescribed liraglutide 3.0 mg, 26.0% were prescribed lorcaserin, 36.3% of patients were prescribed naltrexone-bupropion, 5.4% were prescribed orlistat, and 21.6% were prescribed phentermine-topiramate. Most patients (91.1%) exhibited PNA, with only 8.9% filling their newly prescribed AOM within 60 days. Both the adherent and nonadherent groups were predominately female sex, White, and covered by commercial insurance. The mean age was similar between the 2 groups. Most obesity-related complications were less prevalent in the adherent group, although the Charlson comorbidity index score was similar between the 2 groups. After adjustment for patient demographics and clinical characteristics, there was not a statistically significant association between the specific AOM and PNA ( P = 0.299). Patients with depression or living in the Midwest or South regions were at significantly increased risk of PNA. CONCLUSIONS: The rate of PNA to AOMs was very high, suggesting barriers in effective medical management of patients with overweight and obesity. Future research is warranted to understand reasons for PNA to AOMs and how to address these barriers. DISCLOSURES: Dr Kan, Dr Bae, Dr Dunn, and Dr Ahmad are employees of Eli Lilly and Company. Ms Buysman and Dr Gronroos are employees of Optum. Dr Swindle was an employee of Optum at the time the study was conducted and is currently employed at Evidera. Dr Bengtson is employed at Boehringer Ingelheim Pharmaceuticals, Inc. (Boehringer Ingelheim has no connection to this study), and during the conduct of this study was employed at Optum.- Published
- 2023
- Full Text
- View/download PDF
38. Healthcare Resource Utilization, Cost and Clinical Outcomes in Patients Diagnosed with COPD Initiating Tiotropium Bromide/Olodaterol versus Fluticasone Furoate/Umeclidinium/Vilanterol Based on Exacerbation History.
- Author
-
Sethi S, Clark B, Bengtson LGS, Buysman EK, Palli S, Sargent A, Shaikh A, and Ferguson GT
- Subjects
- Humans, Adult, Tiotropium Bromide, Administration, Inhalation, Bronchodilator Agents, Benzyl Alcohols, Chlorobenzenes, Quinuclidines, Fluticasone therapeutic use, Patient Acceptance of Health Care, Drug Combinations, Pulmonary Disease, Chronic Obstructive diagnosis, Pulmonary Disease, Chronic Obstructive drug therapy, Pulmonary Disease, Chronic Obstructive epidemiology, Pneumonia diagnosis, Pneumonia drug therapy, Pneumonia chemically induced
- Abstract
Background: ATS and GOLD guidelines recommend treating low-exacerbation risk COPD patients with dual (LAMA/LABA) agents and reserving triple therapy (TT; LAMA/LABA and inhaled corticosteroids [ICS]) for severe cases with higher-exacerbation risk. However, TT often is prescribed across the COPD spectrum. This study compared COPD exacerbations, pneumonia diagnosis, healthcare resource utilization, and costs for patients initiating tiotropium bromide/olodaterol (TIO/OLO) and a TT, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI), stratified by exacerbation history., Methods: COPD patients who initiated TIO/OLO or FF/UMEC/VI between 06/01/2015-11/30/2019 (index date=first pharmacy fill-date with ≥30 consecutive treatment days) were identified from the Optum Research Database. Patients were ≥40 years old and continuously enrolled for 12 months during the baseline period and ≥30 days during follow-up. Patients were stratified into GOLD A/B (0-1 baseline non-hospitalized exacerbation), No exacerbation (subset of GOLD A/B), and GOLD C/D (≥2 non-hospitalized and/or ≥1 hospitalized baseline exacerbation). Baseline characteristics were balanced with propensity score matching (1:1). Adjusted risks of exacerbation, pneumonia diagnosis, and COPD and/or pneumonia-related utilization and costs were evaluated., Results: Adjusted exacerbation risk was similar in GOLD A/B and No exacerbation subgroups, and lower in GOLD C/D for FF/UMEC/VI versus TIO/OLO initiators (hazard ratio: 0.87; 95% CI: 0.78, 0.98, p=0.020). Adjusted pneumonia risk was similar between cohorts across the GOLD subgroups. Adjusted COPD and/or pneumonia-related population annualized pharmacy costs were significantly higher for FF/UMEC/VI versus TIO/OLO initiators across subgroups, p<0.001. Adjusted COPD and/or pneumonia-related population annualized total healthcare costs were significantly higher for FF/UMEC/VI versus TIO/OLO initiators in the GOLD A/B and No exacerbation, subgroups, p<0.001 (cost ratio [95% CI]: 1.25 [1.13, 1.38] and 1.21 [1.09, 1.36], respectively), but similar in the GOLD C/D subgroup., Conclusion: These real-world results support ATS and GOLD recommendations for treating low-exacerbation risk COPD patients with dual bronchodilators and TT for more severe, higher-exacerbation risk COPD patients., Competing Interests: Clark and Shaikh are employees of Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI). Palli was employed by BIPI at the time of study. Buysman and Sargent are employees of Optum, which was contracted by BIPI to conduct this study. Bengtson was employed by Optum at the time of study. Sethi of Jacobs School of Medicine and Biomedical Sciences at University at Buffalo and Ferguson of the Department of Medicine, Pulmonary Research Institute of Southeast Michigan are subject matter clinical experts contracted by BIPI for this study. Sethi declares that he has received honoraria/fees for consulting/speaking from AstraZeneca, BIPI, Chiesi, GlaxoSmithKline, Merck and Uptodate. He has received consulting fees for serving on Data safety monitoring boards from Nuvaira, Inc. and Pulmotect, Inc. He has received consulting fees from Apellis Pharmaceuticals and Aerogen Pharma. His institution has received research funds for his participation in Clinical Trials from Regeneron Pharma, Sanofi, Theravance and AstraZeneca. Ferguson reports consulting fees from BIPI, AstraZeneca, DevPro, Syneos Health, GlaxoSmithKline, Teva, Orpheris and Verona Pharma, speaker fees from GlaxoSmithKline and Theravance and is in receipt of research grants from AstraZeneca, Chiesi Novartis International AG, Teva, Galderma, Syneos, PPD, Orpheris, Verona Pharma and GlaxoSmithKline. The authors report no other conflicts of interest in this work., (© 2023 Sethi et al.)
- Published
- 2023
- Full Text
- View/download PDF
39. COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA.
- Author
-
Hanania NA, Bunner SH, Bengtson LGS, Ismaila AS, and Bogart M
- Subjects
- Humans, Female, Aged, Male, Bronchodilator Agents adverse effects, Retrospective Studies, Administration, Inhalation, Fluticasone therapeutic use, Androstadienes adverse effects, Benzyl Alcohols adverse effects, Chlorobenzenes adverse effects, Quinuclidines adverse effects, Patient Acceptance of Health Care, Drug Combinations, Pulmonary Disease, Chronic Obstructive diagnosis, Pulmonary Disease, Chronic Obstructive drug therapy
- Abstract
Purpose: To examine the impact of initiating fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) in a single device on chronic obstructive pulmonary disease (COPD) exacerbations, COPD exacerbation-related costs, and all-cause and COPD-related healthcare resource utilization (HCRU) and costs in patients with COPD., Methods: Retrospective database analysis of patients with COPD aged ≥40 years who initiated FF/UMEC/VI between September 1, 2017, and December 31, 2018 (index date: first pharmacy claim for FF/UMEC/VI), following evidence of multiple-inhaler triple therapy (MITT) (≥30 consecutive days) in the year prior to index. COPD exacerbations, COPD exacerbation-related costs, and all-cause and COPD-related HCRU and costs were compared between the baseline period (12 months prior to and including index) and follow-up period (12 months following index)., Results: Data from 912 patients (mean [SD] age: 71.2 [8.1], 51.2% female) were included in the analyses. Among the overall cohort, mean count of total COPD exacerbations (moderate or severe) per patient was statistically significantly lower in the follow-up period compared to baseline (1.2 vs 1.4, p=0.001). The proportion of patients with ≥1 COPD exacerbation (moderate or severe) was also statistically significantly lower in the follow-up period compared to baseline (56.4% vs 62.4%, p=0.001). All-cause and COPD-related HCRU were similar during follow-up compared to baseline, although the proportion of patients with COPD-related ambulatory visits was lower during follow-up (p<0.001). COPD-related office visit costs, emergency room visit costs, and pharmacy costs were statistically significantly lower during follow-up compared to baseline (p<0.001; p=0.019; p<0.001, respectively)., Conclusion: In a real-world setting, patients on MITT who subsequently initiated FF/UMEC/VI in a single device had significant reductions in the rate of COPD exacerbations (moderate or severe). Switching to FF/UMEC/VI also resulted in improvements in some HCRU and cost outcomes. These data support the use of FF/UMEC/VI among patients at high risk of exacerbation to reduce future risk and improve outcomes., Competing Interests: The authors declare the following conflicts of interest during the last three years in relation to this manuscript: NAH reports research support from AstraZeneca, Boehringer Ingelheim, Genentech, GSK, Novartis, and Sanofi; and is a consultant for Amgen, AstraZeneca, Boehringer Ingelheim, GSK, Novartis, Regeneron Pharmaceuticals, Inc., Sanofi, and Teva. LGSB is an employee of Optum, which received research funds from GSK to conduct this study, although not for manuscript development. SHB was an employee of Optum at the time of study conduct. ASI is an employee of and holds stocks/shares in GSK. ASI is also an unpaid part-time professor at McMaster University, Hamilton, ON, Canada. MB was a permanent employee of, and held stock/shares in, GSK at the time of study conduct. He is now an employee of Gilead Sciences, Foster City, CA, USA. The authors report no other conflicts of interest in this work., (© 2023 Hanania et al.)
- Published
- 2023
- Full Text
- View/download PDF
40. Trends and Characteristics of Global Initiative for Chronic Obstructive Lung Disease Guidelines-Discordant Prescribing of Triple Therapy Among Patients with COPD.
- Author
-
Bhatt SP, Blauer-Peterson C, Buysman EK, Bengtson LGS, and Palli SR
- Abstract
Background: Triple therapy (long-acting muscarinic antagonist [LAMA] plus long-acting beta2-agonist [LABA] plus inhaled corticosteroid [ICS]) is recommended by the Global initiative for chronic Obstructive Lung Disease (GOLD) for moderate-to-severe chronic obstructive pulmonary disease (COPD) with a history of frequent and/or severe exacerbation(s) and dyspnea while using dual bronchodilators. However, many patients receive triple therapy contrary to these recommendations. This study describes factors associated with GOLD-discordant triple therapy initiation., Methods: This retrospective analysis included patients aged 40 and above, with ≥1 COPD diagnosis, who initiated triple therapy (initiation=index date) during the period January 1, 2014 to December 31, 2018 and had ≥12 months pre-index continuous enrollment (baseline). Triple therapy comprised ≥30 days of overlapping LAMA, LABA, and ICS treatments (open triple therapy), or single-inhaler fluticasone furoate/umeclidinium/vilanterol (closed triple therapy). Cohorts were defined based on the absence of baseline maintenance medication use ("maintenance-naïve"), and/or exacerbations ("exacerbation-discordant"), or "dual-discordant" (discordant on both measures). All triple therapy initiators, overall and for each cohort, were described, and predictors of GOLD-discordant triple therapy initiation were identified., Results: Among 21,711 triple therapy initiators, 34.4% were maintenance-naïve, 61.9% exacerbation-discordant, and 22.2% dual-discordant. Triple therapy initiation appeared to increase during the period 2016 to 2018. In 2018 alone, 31.9% and 58.3% of open triple therapy patients were maintenance-naïve and exacerbation-discordant, respectively, versus 37.6% and 64.4% of closed triple therapy patients. Closed triple therapy initiators had 1.65 times greater risk of dual discordance than open triple therapy initiators. Exacerbation-discordant patients initiating closed triple therapy were 1.61 times more likely to be maintenance-naïve than those initiating open triple therapy., Conclusion: A substantial proportion of COPD patients initiating triple therapy do not meet GOLD recommendations regarding exacerbation history and/or prior maintenance therapy. Compared with open triple therapy, closed triple therapy initiators were more likely to be dual discordant., (JCOPDF © 2022.)
- Published
- 2022
- Full Text
- View/download PDF
41. Corrigendum to 'Meningococcal vaccination in patients with newly diagnosed asplenia in the United States' [Vaccine 39 (2021) 272-281].
- Author
-
Ghaswalla PK, Bengtson LGS, Marshall GS, Buikema AR, Bancroft T, Schladweiler KM, Koep E, Novy P, and Hogea CS
- Published
- 2022
- Full Text
- View/download PDF
42. Treatment Patterns and Disease Burden Associated with Multiple-Inhaler Triple-Therapy Use in Asthma.
- Author
-
Oppenheimer J, Bogart M, Bengtson LGS, White J, Sundquist K, Lima R, and Averell C
- Subjects
- Administration, Inhalation, Adrenal Cortex Hormones, Adrenergic beta-2 Receptor Agonists therapeutic use, Bronchodilator Agents therapeutic use, Cost of Illness, Humans, Nebulizers and Vaporizers, Retrospective Studies, Asthma chemically induced, Asthma drug therapy, Asthma epidemiology, Pulmonary Disease, Chronic Obstructive drug therapy
- Abstract
Background: Addition of a long-acting muscarinic antagonist is recommended for patients with asthma uncontrolled on inhaled corticosteroid/long-acting β
2 -agonist therapy. This is the first large-scale, real-world study examining multiple-inhaler triple-therapy (MITT) use in asthma., Objective: To describe real-world prevalence, outcomes, and treatment patterns associated with MITT., Methods: This retrospective cohort study used medical and pharmacy claims from the Optum Research Database. Patients were diagnosed with asthma between January 01, 2013, and July 31, 2018, with evidence of MITT use (≥1 overlapping days' supply of inhaled corticosteroid, long-acting β2 -agonist, and long-acting muscarinic antagonist). Annual MITT prevalence (primary end point) was assessed in the prevalent population; eligible patients were 18 years or older with 2 or more asthma diagnoses during the study period, and continuous enrollment for the entire year. Secondary outcomes (adherence [proportion of days covered], MITT persistence, health care resource utilization, costs) were assessed in the incident MITT population; eligible patients were 18 years or older, with 2 or more asthma diagnoses and continuous enrollment during both the 12-month baseline and 12-month follow-up periods. Patients with chronic obstructive pulmonary disease or cystic fibrosis were excluded., Results: MITT prevalence was low but increased from 0.35% (95% CI, 0.32-0.37) in 2014/2015 to 1.00% (95% CI, 0.96-1.04) in 2017/2018. Among 1831 incident MITT users, there was a substantial disease burden, demonstrated by high health care resource utilization and exacerbation rates. Adherence and persistence to MITT was low (mean proportion of days covered, 0.31 ± 0.27), and 12% (n = 216) remained on MITT 12 months postinitiation., Conclusions: Overall, MITT use among patients with asthma is low. Patients initiating MITT have substantial disease burden and significant unmet needs., (Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
43. Meningococcal vaccination in patients with newly diagnosed asplenia in the United States.
- Author
-
Ghaswalla PK, Bengtson LGS, Marshall GS, Buikema AR, Bancroft T, Schladweiler KM, Koep E, Novy P, and Hogea CS
- Subjects
- Child, Humans, Retrospective Studies, United States, Vaccination, Vaccines, Conjugate, Meningococcal Infections diagnosis, Meningococcal Infections epidemiology, Meningococcal Infections prevention & control, Meningococcal Vaccines, Neisseria meningitidis
- Abstract
Background: Patients with asplenia are recommended to receive meningococcal ACWY (MenACWY) and B (MenB) vaccines in the United States (US)., Objectives: To examine uptake and time to receipt of meningococcal vaccines in newly diagnosed asplenia patients, and identify factors associated with vaccination., Methods: For this retrospective database analysis, patients were identified from 1/1/2010 (MenACWY) or 1/1/2015 (MenB) through 3/31/2018 from an administrative claims database including commercially insured US patients with ≥1 inpatient or ≥2 outpatient claims with evidence of a new asplenia diagnosis (sickle cell disease was excluded); continuous enrollment for ≥12 months before and ≥6 months after the index date; and age ≥2 (MenACWY) or ≥10 (MenB) years. Co-primary outcomes were uptake and time to receipt of ≥1 dose, separately for MenACWY and MenB, by Kaplan-Meier analysis. Cox proportional hazards regression models were used to identify characteristics associated with vaccination., Results: Among 2,273 and 741 patients eligible for the MenACWY and MenB analyses, respectively, 28.1% and 9.7% received MenACWY and MenB in the first 3 years after a new asplenia diagnosis. Patients were more likely to receive meningococcal vaccines if they had received pneumococcal vaccines (MenACWY: hazard ratio [HR] 26.02; 95% confidence interval [CI] 21.01-32.22; MenB: HR 3.89; 95% CI 2.07-7.29) or attended ≥1 well-care visit (MenACWY: HR 6.63; 95% CI 4.84-9.09; MenB: HR 11.17; 95% CI 3.02-41.26)., Conclusions: Meningococcal vaccination rates among newly diagnosed asplenia patients were low, highlighting the need to educate providers about the recommendations for high-risk conditions and ensure healthcare access for vulnerable patients., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [PKG, PN, and CSH are employed by and hold shares in the GSK group of companies. LGSB, ARB, TB, KMS, and EK are employees of Optum, which was contracted by the GSK group of companies to conduct this research. GSM reports involvement as an investigator and consultant for the GSK group of companies, Merck, Seqirus, Pfizer, and Sanofi Pasteur and also as a speaker for Pfizer and Sanofi Pasteur. The authors report no other financial and non-financial relationships and activities.], (Copyright © 2020 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
44. Healthcare Resource Utilization, Exacerbations, and Readmissions Among Medicare Patients with Chronic Obstructive Pulmonary Disease After Long-Acting Muscarinic Antagonist Therapy Initiation with Soft Mist versus Dry Powder Inhalers.
- Author
-
Singer D, Bengtson LGS, Elliott C, Buikema AR, and Franchino-Elder J
- Subjects
- Administration, Inhalation, Adrenergic beta-2 Receptor Agonists adverse effects, Adult, Aged, Bronchodilator Agents adverse effects, Delivery of Health Care, Disease Progression, Dry Powder Inhalers, Female, Humans, Male, Medicare, Patient Readmission, United States epidemiology, Muscarinic Antagonists adverse effects, Pulmonary Disease, Chronic Obstructive diagnosis, Pulmonary Disease, Chronic Obstructive drug therapy, Pulmonary Disease, Chronic Obstructive epidemiology
- Abstract
Background: Chronic obstructive pulmonary disease (COPD) is often managed with inhaled long-acting muscarinic antagonists (LAMAs), yet real-world data on healthcare resource utilization (HRU) by inhaler type are lacking. This study compared HRU after LAMA initiation with a soft mist inhaler (SMI) versus a dry powder inhaler (DPI)., Patients and Methods: Inclusion criteria were COPD diagnosis, age ≥40 years, LAMA initiation (index date = first LAMA SMI or DPI claim 9/1/14-6/30/18), and Medicare Advantage enrollment 1 year pre-index (baseline) to ≥30 days post-index (follow-up). Patients were followed to the earliest of discontinuation, switch, disenrollment, 1 year, or study end (7/31/18). Exclusion criteria were asthma, cystic fibrosis, or lung cancer diagnoses, unavailable demographics, multiple index LAMAs, or baseline LAMA use. Cohorts (SMI or DPI) were balanced on baseline characteristics using inverse probability of treatment weighting. Outcomes included per patient per month (PPPM) COPD-related HRU encounters, and exacerbations (defined as moderate [ambulatory visit with corticosteroid or antibiotic within ±7 days] or severe [emergency visit or inpatient admission]); and 30-day readmissions following COPD-related hospitalizations., Results: After weighting, cohorts (SMI [n=5360] and DPI [n=22,880]) were similar in age (72 and 73 years, respectively), gender (both 52% female), and COPD severity score (31.3 and 31.5, respectively). Cohorts had similar counts of follow-up HRU encounters. However, the SMI cohort had fewer (mean ± standard deviation) COPD-related exacerbations (0.054±0.082 vs DPI cohort 0.059±0.088 PPPM, p<0.001) overall. Moreover, the SMI cohort had fewer severe exacerbations (0.030±0.058 vs DPI: 0.034±0.065 PPPM, p<0.001). Hospitalizations among SMI patients had a lower adjusted odds of readmission versus hospitalizations among DPI patients (odds ratio: 0.656, 95% confidence interval= 0.460, 0.937; p=0.020)., Conclusion: SMI initiators had significantly fewer COPD-related exacerbations than DPI initiators. In addition, lower odds of readmissions were observed following COPD-related hospitalizations among the SMI cohort, as compared with the DPI cohort., Competing Interests: LGSB, CE, and ARB are employees of Optum, Eden Prairie, MN; employment is not contingent upon this work. DS and JF-E are employees of BIPI. The authors report no other conflicts of interest in this work., (© 2020 Singer et al.)
- Published
- 2020
- Full Text
- View/download PDF
45. Association of Multimorbidity with Cardiovascular Endpoints and Treatment Effectiveness in Patients 75 Years and Older with Atrial Fibrillation.
- Author
-
Claxton JS, Chamberlain AM, Lutsey PL, Chen LY, MacLehose RF, Bengtson LGS, and Alonso A
- Subjects
- Aged, Aged, 80 and over, Arthritis epidemiology, Atrial Fibrillation complications, Atrial Fibrillation epidemiology, Coronary Artery Disease epidemiology, Dementia epidemiology, Diabetes Mellitus epidemiology, Female, Humans, Hyperlipidemias epidemiology, Hypertension epidemiology, Male, Neoplasms epidemiology, Proportional Hazards Models, Pulmonary Disease, Chronic Obstructive epidemiology, Renal Insufficiency, Chronic epidemiology, Stroke etiology, Stroke prevention & control, Treatment Outcome, Anti-Arrhythmia Agents therapeutic use, Anticoagulants therapeutic use, Atrial Fibrillation drug therapy, Heart Failure epidemiology, Hemorrhage epidemiology, Hospitalization statistics & numerical data, Multimorbidity, Stroke epidemiology
- Abstract
Background: The burden imposed by multimorbidity on outcomes and on the effectiveness of atrial fibrillation therapies in elderly adults with atrial fibrillation is unknown., Methods: Patients with nonvalvular atrial fibrillation ages ≥75 years in the MarketScan Medicare Supplemental database from 2007-2015. Prevalence of 14 chronic conditions at the time of atrial fibrillation diagnosis were obtained and classified as cardiometabolic or noncardiometabolic. Cox regression estimated the associations of the number and type of conditions with stroke, severe bleeding, and heart failure hospitalizations. Tests for interaction were assessed between atrial fibrillation treatments and multimorbidity., Results: Among 275,617 patients with atrial fibrillation (mean age 83 years, 51% women), the mean (SD) number of conditions per participant was 3.0 (2.1). Over a mean follow-up of 23 months, 7814 strokes, 13,622 severe bleeds, and 19,252 heart failure events occurred. After adjustment, an increase in the number of cardiometabolic conditions was associated with greater risk of stroke (hazard ratio [HR] 1.07; 95% confidence interval [CI], 1.05-1.10), severe bleeding (HR 1.09; 95% CI, 1.07-1.11), and heart failure (HR 1.19, 95% CI, 1.18-1.20). In contrast, number of noncardiometabolic conditions had weak or null associations with risk of cardiovascular endpoints. Overall, the effectiveness of atrial fibrillation treatment on stroke and heart failure were similar across multimorbidity status, but bleeding risk associated with atrial fibrillation treatments was higher in patients with overall and subgroup multimorbidity., Conclusion: Cardiometabolic multimorbidity was associated with worse outcomes and modified bleeding risk in atrial fibrillation patients. These findings underscore the impact of cardiometabolic conditions on atrial fibrillation outcomes and highlights the need to incorporate multimorbidity management in atrial fibrillation treatment guidelines., (Copyright © 2020. Published by Elsevier Inc.)
- Published
- 2020
- Full Text
- View/download PDF
46. Validation and Assessment of the COPD Treatment Ratio as a Predictor of Severe Exacerbations.
- Author
-
Stanford RH, Korrer S, Brekke L, Reinsch T, and Bengtson LGS
- Abstract
Background: Population-based risk assessments are needed to identify individuals who may benefit from chronic obstructive pulmonary disease (COPD) management programs for preventing exacerbations. This study compared the validated COPD treatment ratio (CTR) versus other COPD exacerbation predictors: prior exacerbation and rescue and maintenance medication use., Methods: A retrospective observational study using medical and pharmacy claims data among Medicare Advantage with Part D beneficiaries with COPD (January 2011-August 2016). Unadjusted and adjusted logistic regression models tested the predictive performance (C-statistic) of potential exacerbation predictors for future severe exacerbations., Results: The unadjusted association between exacerbation predictors and severe exacerbation was examined in 60,776 patients: baseline severe exacerbation had the highest C-statistic (0.668), then number of rescue units dispensed (0.651), CTR (0.619), and number of controller units dispensed (0.562). During the at-risk period, baseline CTR was inversely associated with severe exacerbation (odds ratio, <1.0); other predictors were positively associated with a severe exacerbation (odds ratio, >1.0). Adjusting for age, geographic region, chronic oxygen, and nebulizer use, the severe exacerbation odds were 0.90 (95% confidence interval [CI], 0.89-0.91) lower per 0.10 change in CTR (C-statistic, 0.710). The C-statistic was 0.734 when baseline exacerbation was added to the model., Conclusions: The CTR is an effective tool for identifying patients diagnosed with COPD who are at increased risk of severe exacerbation. Although CTR does not predict future exacerbation as well as prior severe exacerbation history, it has the advantage of being applicable in predicting future exacerbations in patients without an exacerbation history, or in databases limited to pharmacy claims only. In addition, the significant reduction in risk has been observed with incremental increases in the ratio: the ratio can be monitored to assess COPD health improvements over time., Competing Interests: The authors declare the following conflicts of interest during the last 3 years in relation to this article: At the time of the study, RHS was an employee of GlaxoSmithKline plc and holds stock options/shares. At the time of the study, TR was a fellow at UNC. SK, LB, and LGSB are employees of Optum; GlaxoSmithKline plc contracted with Optum to conduct this research., (JCOPDF © 2020.)
- Published
- 2020
- Full Text
- View/download PDF
47. Sex and racial differences in cardiovascular disease risk in patients with atrial fibrillation.
- Author
-
O'Neal WT, Alam AB, Sandesara PB, Claxton JS, MacLehose RF, Chen LY, Bengtson LGS, Chamberlain AM, Norby FL, Lutsey PL, and Alonso A
- Subjects
- Aged, Female, Humans, Male, Risk, Sex Distribution, Atrial Fibrillation epidemiology, Racial Groups statistics & numerical data
- Abstract
Background: Outcomes among atrial fibrillation (AF) patients may differ according to race/ethnicity and sex due to differences in biology, the prevalence of cardiovascular risk factors, and the use and effectiveness of AF treatments. We aimed to characterize patterns of cardiovascular risk across subgroups of AF patients by sex and race/ethnicity, since doing so may provide opportunities to identify interventions. We also evaluated whether these patterns changed over time., Methods: We utilized administrative claims data from the Optum Clinformatics® Datamart database from 2009 to 2015. Patients with AF with ≥6 months of enrollment prior to the first non-valvular AF diagnosis were included in the analysis. Final analysis utilized Cox proportional hazard models to estimate adjusted hazard ratios (HR) and 95% confidence intervals (CI) for cardiovascular outcomes stratified by sex and race/ethnicity. An additional analysis stratified outcomes by calendar year of AF diagnosis to evaluate changes in outcomes over time., Results: In a cohort of 380,636 AF patients, women had a higher risk of ischemic stroke [HR (95% CI): 1.25 (1.19, 1.31)] and lower risk of heart failure and myocardial infarction [HR (95% CI): 0.91 (0.88, 0.94) and 0.81 (0.77, 0.86), respectively)] compared to men. Black patients had elevated risk across all endpoints compared to whites, while Hispanics and Asian Americans showed no significant differences in any outcome compared to white patients. These sex and race/ethnic differences did not change over time., Conclusions: We found sex and race/ethnic differences in risk of cardiovascular outcomes among AF patients, without evidence of improvement over time., Competing Interests: LGSB is employed by Optum, but neither they nor the rest of the authors have had special access or privileges to the Optum data that others would not have. This does not alter our adherence to PLOS ONE policies on sharing data and materials, with the restrictions stated above. Authors do not have any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products.
- Published
- 2019
- Full Text
- View/download PDF
48. A new model to predict ischemic stroke in patients with atrial fibrillation using warfarin or direct oral anticoagulants.
- Author
-
Claxton JS, MacLehose RF, Lutsey PL, Norby FL, Chen LY, O'Neal WT, Chamberlain AM, Bengtson LGS, and Alonso A
- Subjects
- Administration, Oral, Aged, Anticoagulants administration & dosage, Brain Ischemia etiology, Female, Humans, Male, Models, Statistical, Predictive Value of Tests, Prognosis, Reproducibility of Results, Risk Factors, Atrial Fibrillation complications, Atrial Fibrillation drug therapy, Factor Xa Inhibitors administration & dosage, Risk Assessment methods, Stroke diagnosis, Stroke etiology, Stroke prevention & control, Warfarin administration & dosage
- Abstract
Background: Stroke risk stratification scores (eg, CHA
2 DS2 -VASc) are used to tailor therapeutic recommendations for patients with atrial fibrillation (AF) in different risk groups., Objective: The purpose of this study was to develop a tool to estimate stroke risk in patients receiving oral anticoagulants (OACs) and to identify patients who remain at high risk for stroke despite anticoagulation therapy., Methods: Patients with nonvalvular AF initiating OACs were identified in the MarketScan data from 2007 to 2015. Using bootstrapping methods and backward selection of 44 candidate variables, we developed a model that selected variables predicting stroke. The final model was validated in patients with nonvalvular AF in the Optum database in the period 2009-2015. In both databases, the discrimination of existing stroke scores were individually evaluated and compared with our new model termed the AntiCoagulaTion-specific Stroke (ACTS) score., Results: Among 135,523 patients with AF initiating OACs in the MarketScan dataset, 2028 experienced an ischemic stroke after anticoagulant initiation. The stepwise model identified 11 variables (including type of OAC) associated with ischemic stroke. The discrimination (C statistic) of the model was adequate (0.68; 95% confidence interval [CI] 0.66-0.70), showing excellent calibration (χ2 = 6.1; P = .73). ACTS was then applied to 84,549 AF patients in the Optum dataset (1408 stroke events) and showed similar discrimination (C statistic 0.67; 95% CI 65-0.69). However, previously developed predictive models had similar discriminative ability (CHA2 DS2 -VASc 0.67; 95% CI 0.65-0.68)., Conclusion: A novel model to identify AF patients at higher risk of ischemic stroke, using extensive administrative health care data including type of anticoagulant, did not perform better than established simpler models., (Copyright © 2018 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
49. CHA 2 DS 2 -VASc Score and Stroke Prediction in Atrial Fibrillation in Whites, Blacks, and Hispanics.
- Author
-
Chen LY, Norby FL, Chamberlain AM, MacLehose RF, Bengtson LGS, Lutsey PL, and Alonso A
- Abstract
Background and Purpose- Despite modest predictive ability for ischemic stroke (IS), the CHA
2 DS2 -VASc score is widely used for stroke prediction in atrial fibrillation. Among patients with atrial fibrillation, we aimed to (1) compare the IS or transient ischemic attack (TIA) incidence by CHA2 DS2 -VASc in blacks and Hispanics versus whites; (2) compare predictive ability of CHA2 DS2 -VASc score for IS or TIA in blacks and Hispanics versus whites; and (3) determine improvement in predictive ability of CHA2 DS2 -VASc score from addition of race/ethnicity. Methods- Using data from Optum Clinformatics, a large administrative claims database, we analyzed patients with atrial fibrillation enrolled in commercial and Medicare Advantage health plans from 2009 to 2015. We computed IS or TIA incidence rates, improvement in C statistic, continuous and categorical net reclassification improvement, and relative integrated discrimination improvement from addition of race/ethnicity to CHA2 DS2 -VASc. Results- A total of 267 419 patients (mean age, 73.1 [SD, 12.3] years; 46.6% women; 84.2% white, 8.5% black, 7.3% Hispanic) were studied. After a mean follow-up of 22 months, there were 6202 IS or TIA events. IS or TIA incidence rates were higher in blacks than Hispanics or whites (1.65, 1.40, and 1.22 cases per 100 person-years, respectively) and increased with higher CHA2 DS2 -VASc, with no race/ethnicity-based differences ( P for interaction=0.17). The CHA2 DS2 -VASc and CHA2 DS2 -VASc+race/ethnicity C statistic (95% CI) were 0.679 (0.670-0.686) and 0.679 (0.671-0.688). The CHA2 DS2 -VASc C statistic in the 3 groups were comparable. With addition of race/ethnicity, the categorical net reclassification improvement, continuous net reclassification improvement, and relative integrated discrimination improvement were -0.045 (95% CI, -0.067 to -0.025), 0.045 (95% CI, 0.025-0.068), and 0.016 (95% CI, 0.014-0.018). Conclusions- The predictive ability of CHA2 DS2 -VASc for IS or TIA in atrial fibrillation is comparable among whites, blacks, and Hispanics; hence, it can be used in the latter 2 groups. Addition of race/ethnicity to the CHA2 DS2 -VASc does not improve its predictive ability.- Published
- 2019
- Full Text
- View/download PDF
50. Provider Specialty, Anticoagulation, and Stroke Risk in Patients With Atrial Fibrillation and Cancer.
- Author
-
O'Neal WT, Claxton JS, Sandesara PB, MacLehose RF, Chen LY, Bengtson LGS, Chamberlain AM, Norby FL, Lutsey PL, and Alonso A
- Subjects
- Administration, Oral, Aged, Comorbidity, Female, Hemorrhage chemically induced, Hemorrhage epidemiology, Humans, Male, Middle Aged, Outcome and Process Assessment, Health Care, Risk Adjustment methods, Risk Factors, Stroke epidemiology, Stroke etiology, United States epidemiology, Anticoagulants therapeutic use, Atrial Fibrillation complications, Atrial Fibrillation drug therapy, Atrial Fibrillation epidemiology, Cardiology methods, Cardiology statistics & numerical data, Hemorrhage prevention & control, Neoplasms diagnosis, Neoplasms epidemiology, Stroke prevention & control
- Abstract
Background: It is unknown whether early cardiology involvement shortly after atrial fibrillation (AF) diagnosis is associated with favorable outcomes in AF patients who have cancer., Objectives: The purpose of this study was to examine the relationship between early cardiology involvement after AF diagnosis in patients with history of cancer., Methods: This study examined associations of early cardiology involvement with oral anticoagulation use, stroke, and bleeding among nonvalvular AF patients (n = 388,045; mean age 68 ± 15 years; 59% male) with a history of cancer (past or active) from the MarketScan database (2009 to 2014). International Classification of Disease-9th Revision-Clinical Modification codes in any position were used to identify cancer diagnosis prior to AF diagnosis. Provider specialty and filled anticoagulant prescriptions 3 months prior to and 6 months after AF diagnosis were obtained. Poisson regression models were used to compute the probability of an oral anticoagulant prescription fill, and Cox regression was used to estimate the risks of stroke and major bleeding., Results: A total of 64,016 (17%) AF patients had a history of cancer. Cardiology involvement was less likely to occur among patients with a history of cancer than those without (relative risk [RR]: 0.92 [95% confidence interval (CI): 0.91 to 0.93]). Patients with history of cancer were less likely to fill prescriptions for anticoagulants (RR: 0.89 [95% CI: 0.88 to 0.90]) than those without cancer, and similar results were observed across cancer types. Patients with cancer were more likely to fill prescriptions for anticoagulants (RR: 1.48 [95% CI: 1.45 to 1.52]) if seen by a cardiologist. A reduced risk of stroke (hazard ratio: 0.89 [95% CI: 0.81 to 0.99]) was observed among all cancer patients who were seen by a cardiology provider, without an increased risk of bleeding (hazard ratio: 1.04 [95% CI: 0.95 to 1.13]). Similar results were observed when the analysis was stratified by active versus remote history of cancer., Conclusions: Although AF patients with cancer were less likely to see a cardiologist, or fill anticoagulant prescriptions, cardiology involvement was associated with increased anticoagulant prescription fills and favorable AF-related outcomes in AF patients with cancer., (Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.